All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Many proteins involved in signalling pathways undergo farnesylation; therefore inhibiting farnesyltransferase as a targeted therapy against oncogenic Ras is being explored. Farnesyltransferase inhibitor monotherapy with agents such as tipifarnib have been investigated.